
|Videos|July 23, 2013
Episode 15 - SLE: Expectations As the Drug Market Evolves
Advertisement
Although currently limited, Michelle Petri, MD, MPH, explains that the drug market for treating systemic lupus erythematosus (SLE) is growing. Dr Petri explains that because SLE is a heterogeneous disease that manifests in patients in many different ways, new agents to treat SLE will be classified into a series of different categories.
Dr Petri continues the discussion by exploring the future roles of these new agents which leads the panelists into a conversation about the costs of these treatment options.
Hugh Fatodu, RPh, MBA, and Dr Petri conclude that without proper data that review the long-term outcomes of agents for the treatment of SLE, it is difficult to estimate any economic benefits or advantages.
Advertisement
Related to this article

Panelists concurred that precision medicine can serve to exacerbate care inequality if not everyone can access these therapeutics.

Employer diabetes guide; Camden psychedelic therapy input; CRC after EMR; rural HFrEF care; JAMA obesity report.

This article analyzes gaps in US biosimilar development, quantifies market opportunities, and proposes policy and economic solutions to improve cost savings and patient access.

An employer coalition's new guide outlines how workplaces can prevent and manage diabetes, from benefit design to accommodations.

New York hepatitis B experts say screening gaps and weekly monitoring demands could limit who benefits from the first functional cure therapy.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.
Advertisement
Advertisement



















